Furthermore, there have been studies showing that blocking RIPK1, RIPK3, and MLKL can therefore improve the pulmonary function in diseases such as COPD and ARDS, as well as insulin resistance (230–232); the inhibitors include GW806742X and Nec‐1 (230, 232). This evidence concerns the gene RIPK3 and chronic obstructive pulmonary disease.